|1.||Gonzalez, Frank J: 5 articles (02/2014 - 04/2008)|
|2.||Cuzzocrea, Salvatore: 5 articles (01/2010 - 07/2002)|
|3.||Shah, Yatrik M: 4 articles (02/2014 - 04/2008)|
|4.||Mazzon, Emanuela: 4 articles (01/2010 - 10/2004)|
|5.||Di Paola, Rosanna: 4 articles (01/2010 - 10/2004)|
|6.||König, Bettina: 4 articles (03/2009 - 11/2006)|
|7.||Stangl, Gabriele I: 4 articles (03/2009 - 11/2006)|
|8.||Eder, Klaus: 4 articles (03/2009 - 11/2006)|
|9.||Koch, Alexander: 4 articles (03/2009 - 11/2006)|
|10.||Sugden, Mary C: 4 articles (02/2003 - 06/2002)|
05/01/2015 - "Although PPARα(Δ)ob/ob mice are severely obese, there was no significant increase in liver tumor incidence, even when maintained on a diet containing Wy-14,643. "
04/01/2006 - "Wy-14,643 (WY) is a hypolipidemic drug that induces hepatic peroxisome proliferation and tumors in rodents. "
04/01/2001 - "The potent PP and rodent tumor promoter, pirinixic acid (WY-14643) also inhibited LXR-mediated transcription in a dose related manner (approximate IC(50) of 100 microM). "
01/01/2000 - "In in vivo experiments, the formation of preneoplastic lesions and the tumors caused by Wy-14,643 administration were markedly suppressed by i.v.-injection of HGF in a dose-dependent manner. "
01/01/1994 - "Induction of a 65-kDa tumor-associated protein in altered hepatic foci of rats fed the peroxisome proliferator Wy-14,643."
12/01/2010 - "VP16PPARα mice exhibited massive peroxisome proliferation and hepatomegaly as well as increased mortality upon Wy-14,643 treatment. "
06/01/2001 - "Hepatomegaly was found in both HGF transgenic mouse lines fed WY-14,643 compared with controls. "
01/01/2001 - "When the potent peroxisome proliferator, WY-14,643, was given to hypothyroid rats, there was a blunting of the hepatomegaly and hepatocyte proliferative responses seen in thyroid-intact animals. "
01/01/1992 - "Hepatomegaly was induced by Wy-14,643 at all doses and at all time points. "
11/06/1995 - "In a 42-day study, dietary concentrations of 0.9-2.0% gemfibrozil induced a similar magnitude of hepatomegaly to WY-14,643 (2.3-fold) but a higher level of peroxisome proliferation (16-18-fold) than the maximum induction for WY-14,643 (13-fold). "
05/01/2004 - "In conclusion, the present study shows that MCD diet-induced fibrosing steatohepatitis can be reversed by treatment with Wy-14,643. "
05/01/2009 - "Importantly, WY-14,643 reversed the development of fatty liver in alcohol-fed mice. "
07/01/2003 - "Wy-14,643 prevented rather than increased liver injury; ALT levels were only mildly elevated whereas steatohepatitis was absent. "
05/01/2004 - "We have now tested whether Wy-14,643 ameliorates established steatohepatitis and fibrosis. "
01/01/2015 - "PPARα Agonist WY-14643 Induces SIRT1 Activity in Rat Fatty Liver Ischemia-Reperfusion Injury."
07/05/2013 - "To address the beneficial efficacy of Wy-14643 for ALI along with systemic inflammation, the in vivo role of PPARα activation was investigated in a mouse model of lipopolysaccharide (LPS)-induced ALI. "
12/01/2005 - "Moreover, Wy-14,643 treatment reduced inflammation and the expression of macrophage-specific genes in white adipose tissue (WAT). "
10/01/2009 - "Pirinixic acid (Wy-14,643) is an agonist of the peroxisome proliferator-activated receptor (PPAR) subtype alpha exhibiting beneficial effects in various inflammation-related processes in a slow, long-termed fashion. "
01/01/2015 - "Activation of peroxisome proliferator-activated receptor-α (PPAR-α) by fibrates, such as WY-14643 (WY), has been described to beneficially influence inflammation and experimental lung injury. "
|5.||Acute Lung Injury
|2.||Glycine (Aminoacetic Acid)
|3.||Peroxisome Proliferator-Activated Receptors (PPAR)
|5.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
|10.||Matrix Metalloproteinase 9 (Gelatinase B)